•  •  Dark Mode

Your Interests & Preferences

I am a...

law firm lawyer
in-house company lawyer
litigation lawyer
law student
aspiring student
other

Website Look & Feel

 •  •  Dark Mode
Blog Layout

Save preferences
Subscribe for perks & to support LI

2018’s 50 busiest Supreme Court AOR law firms • Khaitan leads in Big 7 with 213 filings • JSA, SAM also 100+

113 people have already read this article, which will unlock for non-subscribers like you in . So what are you waiting for? Subscribe now!

Majmudar, Veritas act on $20m Japan’s Otsuka pharma buy of Indian JV from Claris Lifesciences

Otsuka Pharmaceutical Factory, Inc, a leading Japanese pharmaceuticals manufacturing company, has announced a proposal to acquire an additional 20% stake from its joint venture partner, Claris Lifesciences Limited for a consideration of about Rs 128.9 crores (US$20 million) in its existing Indian joint venture, Otsuka Pharmaceutical India Private Limited, as reported by Business Standard.

Majmudar & Partners Mumbai partner Rukshad Davar represented and acted for Otsuka Pharmaceutical Factory on this transaction, according to the firm’s statement.

Veritas Legal partner Abhijit Joshi and partner Tushar Raut and associate Rebha Dakshini represented and acted for Claris Lifesciences Limited.

The proposed acquisition is subject to approval of the Foreign Investment Promotion Board.

Click to show 1 comment
at your own risk
(alt+c)
By reading the comments you agree that they are the (often anonymous) personal views and opinions of readers, which may be biased and unreliable, and for which Legally India therefore has no liability. If you believe a comment is inappropriate, please click 'Report to LI' below the comment and we will review it as soon as practicable.

Latest comments